제품 > 항체 > Biosimilar Antibody

Human TNF alpha Monoclonal Antibody (YR0014)

Direct ELISA binding curve demonstrating the recognition of Human Anti-Human TNF-α (Research Grade Infliximab Biosimilar) Monoclonal Antibody to TNF-α. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.

Human TNF-α SPR assay. Determined through SPR assay, the Human Anti-Human TNF-α (Research Grade InfliximabBiosimilar) Monoclonal Antibody is Capable of binding to Human TNF-α with an affinity constant of 84.49 pM.

Basic Information

Clone	Infliximab Biosimilar
Molecular Weight	150 kDa
Endotoxin	<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay
Sterility	0.2 μm filtration
Aggregation	<5% Determined by SECP
Purity	>95% Determined by SDS-PAGE

Product Information

Production	Purified from cell culture supernatant in an animal-free facility
Purification	Protein A or G purification
Storage	2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Target Background

Infliximab, a chimeric anti-TNF-α monoclonal antibody, is used to treat psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. Infliximab interferes TNF-α from binding to its receptor in the cell.Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of autoimmune reaction.

Immunogen Information

Isotype	Human IgG1 kappa
Immunogen	Human TNF alpha
RecommendedIsotype Control(s)	In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody
Recommended Dilution Buffer	1×PBS pH 7.0